CC
ALXN

Carlson Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Carlson Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-679,150
Closed -$125M – 213
2021
Q2 		$125M Buy
679,150
+65,759
+11% +$11.3M 6.02% 3
2021
Q1 		$93.8M Buy
613,391
+128,391
+26% +$19.9M 3.49% 5
2020
Q4 		$75.8M Buy
+485,000
New +$62.3M 2.7% 8
2017
Q3 		– Sell
-114,697
Closed -$14M – 279
2017
Q2 		$14M Sell
114,697
-259,803
-69% -$30.2M 0.2% 159
2017
Q1 		$45.4M Buy
374,500
+269,883
+258% +$34.8M 0.58% 53
2016
Q4 		$12.8M Buy
+104,617
New +$12.8M 0.15% 163
2015
Q3 		– Sell
-71,484
Closed -$12.9M – 357
2015
Q2 		$12.9M Buy
+71,484
New +$12.3M 0.14% 189

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Carlson Capital's ALXN Position: Q3 2021 in Review

Carlson Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 679,150 shares — an estimated $125M sold.

Carlson Capital first reported a position in ALXN in Q2 2015 and held it in 7 quarters. The position peaked at $125M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Carlson Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Carlson Capital sold 679,150 Alexion Pharmaceuticals shares in Q3 2021, an estimated $125M.
  • Carlson Capital first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 7 quarters.
  • Carlson Capital's Alexion Pharmaceuticals position peaked at $125M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Carlson Capital's 13F filing for Q3 2021, filed 12 Nov 2021.